Editorial: Resmetirom – a promising treatment option for NASH and liver fibrosis
Alimentary Pharmacology & Therapeutics · 2024
DOI: 10.1111/apt.17747 ↗At a glance
Editorial in Alimentary Pharmacology & Therapeutics, 2024. Written by Giovanni Targher. Institution: Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Verona, Verona, Italy. Major MEDLINE topics: Non-alcoholic Fatty Liver Disease, Pyridazines. Cited 5 times so far (Crossref); 9 references.
Abstract (original language)
LINKED CONTENT This article is linked to Harrison et al paper. To view this article, visit https://doi.org/10.1111/apt.17734
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Verona, Verona, Italy.
- Metabolic Diseases Research Unit, IRCCS Sacro Cuore - Don Calabria Hospital, Negrar di Valpolicella, Italy.
ORCID profiles: Giovanni Targher
Cite
APA
Targher, G. (2024). Editorial: Resmetirom – a promising treatment option for NASH and liver fibrosis. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.17747
Vancouver
Targher G. Editorial: Resmetirom – a promising treatment option for NASH and liver fibrosis. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.17747
BibTeX
@article{Targher2024,
author = {Targher, Giovanni},
title = {Editorial: Resmetirom – a promising treatment option for NASH and liver fibrosis},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2024},
doi = {10.1111/apt.17747}
}
EUVIMED